RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RELIEF THERAPEUTICS Holding - Stock

RELIEF THERAPEUTICS Holding Market capitalization 2024

RELIEF THERAPEUTICS Holding Market capitalization

14.1 M CHF

Ticker

RLF.SW

ISIN

CH0100191136

WKN

A1H80W

In 2024, RELIEF THERAPEUTICS Holding's market cap stood at 14.1 M CHF, a -54.89% increase from the 31.26 M CHF market cap in the previous year.

The RELIEF THERAPEUTICS Holding Market capitalization history

YEARREVENUE (undefined CHF)GROSS MARGIN (%)NET INCOME (undefined CHF)
2028e1.170,37920.41
2027e0.520,83357.7
2026e0.640,6758.21
2025e0.085,630.01
2024e0.049,73-0.01
20230.0171,22-98.18
20220.0179,44-50.79
2021077,42-34.71
2020---7.83
2019---7.46
20180760,53-0.44
2017---2.89
2016028646,67-16.83
2015---0.08
2014---10.78
20130.0229,33-12.22
2012---6.48
2011---59.17
201001101,79-19.4
20090.0131,27-12.21
20080.0129,53-9.4
20070.0128,98-1.61
20060173,27-7.22

RELIEF THERAPEUTICS Holding Aktienanalyse

What does RELIEF THERAPEUTICS Holding do?

RELIEF THERAPEUTICS Holding SA is a Swiss biotech company that specializes in the research and development of novel therapies for the treatment of serious diseases. The company was founded in 2016 and is based in Geneva. The history of RELIEF THERAPEUTICS began with the discovery of a promising molecule called Aviptadil. Aviptadil is a synthetic peptide derived from the natural hormone VIP (Vasoactive Intestinal Peptide). It has the ability to regulate a variety of biological processes in the body and has shown promise as a therapy for a range of diseases. Since its inception, the company has formed a number of partnerships and collaborations with other companies and research institutions to support its research projects and bring its technology to market. The business model of RELIEF THERAPEUTICS is based on the research and development of innovative therapies for a variety of serious diseases for which there is currently no effective treatment. The company focuses on the research and development of peptides and proteins as a new class of therapeutic agents. RELIEF THERAPEUTICS has several business segments active in drug development. The first segment is the respiratory diseases segment, in which the company utilizes its core expertise in the development of Aviptadil to explore innovative therapies for severe respiratory diseases such as idiopathic pulmonary fibrosis (IPF), acute and chronic respiratory distress syndromes (ARDS/CRDS), and asthma. Another important segment of RELIEF THERAPEUTICS is cancer research. The company is working on the development of new cancer therapies based on Aviptadil, targeting the regulation of tumor growth and metastasis formation. The third segment of the company is pain therapy. Here, RELIEF THERAPEUTICS is working on the development of peptide-based analgesics to alleviate pain in various conditions such as cancer, neuropathic pain, and postoperative pain. RELIEF THERAPEUTICS currently offers several products based on Aviptadil. One of these products is RLF-100, also known as ZYESAMI, a potential drug for the treatment of severe respiratory diseases such as ARDS/CRDS and COVID-19. RLF-100 is an inhalable Aviptadil specifically developed for the treatment of respiratory diseases and has shown high efficacy in clinical studies. Another product from RELIEF THERAPEUTICS is RLF-888, a potential drug for the treatment of neuropathic pain. RLF-888 has been developed as a peptide-based analgesic and has shown promising results in preclinical studies. In 2021, RELIEF THERAPEUTICS acquired a majority stake in APR Applied Pharma Research SA, expanding its product range and business areas. APR is increasingly gaining importance in the acute aplastic pain market and could prove to be an important part of RELIEF THERAPEUTICS' product diversity in the future. Overall, RELIEF THERAPEUTICS has positioned itself as a promising player in the biotech industry and continues to strive to develop innovative therapies for serious diseases to help patients worldwide. RELIEF THERAPEUTICS Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring RELIEF THERAPEUTICS Holding's Market Capitalization

RELIEF THERAPEUTICS Holding's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of RELIEF THERAPEUTICS Holding's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

RELIEF THERAPEUTICS Holding's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in RELIEF THERAPEUTICS Holding’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about RELIEF THERAPEUTICS Holding Stock

What is the current RELIEF THERAPEUTICS Holding market capitalization?

The current market capitalization of RELIEF THERAPEUTICS Holding is 14.1 M CHF.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like RELIEF THERAPEUTICS Holding.

How has the market capitalization of RELIEF THERAPEUTICS Holding developed in recent years?

The market capitalization of RELIEF THERAPEUTICS Holding has increased/decreased by -54.89% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of RELIEF THERAPEUTICS Holding?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of RELIEF THERAPEUTICS Holding?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of RELIEF THERAPEUTICS Holding have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does RELIEF THERAPEUTICS Holding pay?

Over the past 12 months, RELIEF THERAPEUTICS Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RELIEF THERAPEUTICS Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of RELIEF THERAPEUTICS Holding?

The current dividend yield of RELIEF THERAPEUTICS Holding is .

When does RELIEF THERAPEUTICS Holding pay dividends?

RELIEF THERAPEUTICS Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RELIEF THERAPEUTICS Holding?

RELIEF THERAPEUTICS Holding paid dividends every year for the past 0 years.

What is the dividend of RELIEF THERAPEUTICS Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is RELIEF THERAPEUTICS Holding located?

RELIEF THERAPEUTICS Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von RELIEF THERAPEUTICS Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RELIEF THERAPEUTICS Holding from 6/30/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.

When did RELIEF THERAPEUTICS Holding pay the last dividend?

The last dividend was paid out on 6/30/2024.

What was the dividend of RELIEF THERAPEUTICS Holding in the year 2023?

In the year 2023, RELIEF THERAPEUTICS Holding distributed 0 CHF as dividends.

In which currency does RELIEF THERAPEUTICS Holding pay out the dividend?

The dividends of RELIEF THERAPEUTICS Holding are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von RELIEF THERAPEUTICS Holding

Our stock analysis for RELIEF THERAPEUTICS Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RELIEF THERAPEUTICS Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.